A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 1999

Study Completion Date

December 31, 2004

Conditions
Fabry Disease
Interventions
DRUG

Fabrazyme (agalsidase beta)

Trial Locations (20)

10029

Mount Sinai School of Medicine, New York

14642

University of Rochester School of Medicine, Rochester

21204

Greater Baltimore Medical Center, Baltimore

28601

Hart Family Practice, Hickory

33065

Northwest Oncology & Hematology Associates, Coral Springs

52242

University of Iowa Hospital and Clinics, Iowa City

59101

Fetal Diagnostic and Imaging Center, Billings

60614

Children's Memorial Hospital, Chicago

78229

Hematology/Oncology Associates of South Texas, San Antonio

87131

University of New Mexico, Albuquerque

90048

Cedars-Sinai Medical Center, Los Angeles

94143

University of California San Fransisco, San Francisco

98195

University of Washington School of Medicine, Seattle

02215

Beth Israel Deaconess Medical Center, Boston

Cedex 03

Hospital Edouard Herriot, Lyon

Cedex 15

Hospital Europeen Georges Pompidou, Paris

1105 AZ

Academisch Medisch Centrum, Amsterdam

00935

University of Puerto Rico, San Juan

WC1N 3BG

National Hospital for Neurology and Neurosurgery, London

M6 8HD

Hope Hospital, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00074971 - A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease | Biotech Hunter | Biotech Hunter